Pain Management after Major Orthopedic Surgery with the Sufentanil Sublingual Microtablet System
|
|
- Brandon Oliver
- 6 years ago
- Views:
Transcription
1 Pain Management after Major Orthopedic Surgery with the Sufentanil Sublingual Microtablet System David W. Griffin, MD Vero Beach, FL
2 Disclosures/Acknowledgements Dr. Griffin received research funding and honorarium support from AcelRx Pharmaceuticals, the sponsor of the study Drs. Minkowitz, Jove, and Melson similarly received research funding for their participation in the trial Drs. Palmer and Royal are officers, employees and shareholders of AcelRx The authors and sponsor would like to thank the study subjects, investigators, research coordinators, and Pharmanet/I3, a subsidiary of Inventiv Health Clinical, for their participation in the trial
3 ZALVISO: Sufentanil sublingual microtablet system (currently under FDA review) Patient-activated bedside system to dispense sufentanil microtablets 15 mcg sublingually with a 20-minute lockout interval 40 microtablets per cartridge is approximately a two-day supply 3
4 Treatment of Pain after Major Orthopedic Surgery: Design features Randomized, Double-Blind, Placebo-Controlled Trial: Efficacy and safety of Zalviso (sufentanil sublingual microtablet system/15 mcg or SSMS) after elective unilateral knee or hip replacement ASA I-III male or female patients 18 years of age or older General or spinal anesthesia that did not include intrathecal opioids Excluded: opioid tolerance (more than 15 mg oral mophine equivalent per day) positive urine drug screen or history of opioid or alcohol dependence or illicit use of drugs of abuse documented sleep apnea use of perioperative regional anesthetic techniques, including neuraxial, intraarticular, peripheral nerve block and local anesthetic wound infiltration 4
5 SSMS and Rescue IV Morphine Dosing In the PACU, pain was first controlled to < 5 (NRS), and then when it was > 4, study drug dosing of SSMS could begin Patients were considered completers after 48 hours of SSMS dosing, however the study extended to 72 hours if needed A 2 mg IV morphine bolus was allowed no more than once an hour as supplemental/rescue analgesia Pain scores were obtained at prespecified timepoints after initial dosing and also prior to each administration of IV MS to allow pre-rescue imputation of pain scores 5
6 Primary and Key Secondary Endpoints 6 Primary endpoint: Weighted sum of pain intensity differences over 48 hours (SPID48) Pain intensity assessed using a numerical rating scale (0-10) Key secondary endpoints: Reasons for dropout Sum of pain relief scores (TOTPAR48) Patient and healthcare professional global assessment of method of pain control at 48 h (PGA48; HPGA48) Validated Patient and Nurse Ease of Care Questionnaires Adverse events
7 Demographics and Early Dropouts Baseline characteristics similar for treatment groups Enrolled 420 [201 knee/219 hip] randomized 3:1 (SSMS:Placebo) 419 randomized and received study drug (315:104) 258 (62%) completed the 48h study period: 215 (68%) in SSMS vs. 43 (41%) in placebo group Reasons for early dropout (most of the other category were early hospital discharges) Zalviso (%) n = 315 Placebo (%) n = 104 Adverse event Lack of efficacy Subject request Other
8 Primary efficacy results Zalviso (SSMS) was superior to placebo for the SPID-48 primary endpoint (p ) Pain response was statistically significant by 60 min p for all time points from 2 to 72h Least Squares Mean of Time-Weighted Summed Pain Intensity Differences by Evaluation Time Point (ITT Population) 8
9 TOTPAR48; PGA48; HPGA48 Similar positive results in favor of Zalviso for the time-weighted summed pain relief over 48h (TOTPAR-48), PGA-48 and HPGA-48 Least Squares Mean of Time-Weighted Summed Pain Relief (TOTPAR) by Evaluation Time Point (ITT Population) % Patients Reporting Success on PGA/HPGA-48 Zalviso n=315 (%) Placebo n=104 (%) P value PGA PGA PGA HPGA HPGA HPGA PGA = Patient global assessment; HPGA = Healthcare professional global assessment
10 Time to termination and time to first rescue Kaplan-Meier Cumulative Event Rate A: Time to Termination due to inadequate analgesia A B: Time to First Rescue B 10
11 Rescue consumption and inter-dosing interval Supplemental/rescue IV morphine consumption was significantly higher in the placebo group at all time points from 6 through 48h (p 0.002) Over 48h, the placebo group used 73% more morphine than the Zalviso group (p ) The mean inter-dosing interval was 84 min for Zalviso vs. 59 min for placebo (p ) 11
12 Adverse events Treatment-emergent AEs occurred in 83.8% and 61.5% of the Zalviso and placebo patients, respectively. No significant differences between the groups for any related AE except nausea and pruritus, both in favor of placebo. Zalviso (n = 315) Placebo (n = 104) p-value* Nausea 110 (34.9%) 23 (22.1%) Vomiting 34 (10.8%) 6 (5.8%) ns Oxygen saturation decreased 22 (7.0%) 3 (2.9%) ns Dizziness 16 (5.1%) 1 (1.0%) ns Constipation 15 (4.8%) 1 (1.0%) ns Pruritus 15 (4.8%) 0 (0.0%) Headache 13 (4.1%) 6 (5.8%) ns Insomnia 13 (4.1%) 3 (2.9%) ns Hypotension 12 (3.8%) 2 (1.9%) ns Based on a two-sided Fisher s exact test. NS = not significant 12
13 Conclusions Zalviso (Sufentanil Sublingual Microtablet System) is superior to placebo for treatment of major orthopedic pain Primary and key secondary endpoints were highly positive in favor of Zalviso The AEs were the type commonly seen after surgery and most were mild to moderate in severity Aside from itching and nausea, there were no statistically significant differences in the adverse event profile between treatment groups
14 14 Questions?
15 Abstract Pain Management after Major Orthopedic Surgery with the Sufentanil Sublingual Microtablet System David W. Griffin, MD 1 ; Harold S. Minkowitz, MD 2 ; Maurice Jove, MD 3 ; Timothy Melson, MD 4 ; Pamela P. Palmer, MD PhD 5,6 ; Mike A. Royal, MD JD 6 1 Orthopedic Center of Vero Beach, Vero Beach, FL; 2 MemorialHermann-Memorial City Medical Center, Houston, TX; 3 Southeaster Center for Clinical Trials/Atlanta Knee and Sports Medicine, Decatur, GA; 4 Helen Keller Hospital, Sheffield, AL; 5 University of California, San Francisco, San Francisco, CA; 6 AcelRx Pharmaceuticals, Redwood City, CA INTRODUCTION: The sufentanil sublingual microtablet system (SSMS; ZALVISO TM ) is a novel handheld, preprogrammed, noninvasive drug/device product which has completed Phase 3 development and is designed to allow patients to easily self-administer sublingual sufentanil 15 mcg microtablets with a 20-minute lockout period. While sufentanil has good cardiac stability, a high therapeutic index and minimal pharmacokinetic population differences, rapid redistribution from plasma and short duration of effect following IV administration limit its usefulness as an analgesic. When dosed sublingually, sufentanil s pharmacokinetic profile and non-invasive delivery makes it a useful alternative to IV PCA. MATERIALS/METHODS: This was a randomized, double-blind, placebo-controlled study in adult inpatients after total hip or knee arthroplasty. Patients expected to require parenteral opioid analgesia for at least 48 hours after surgery were randomized 3:1 (SSMS:placebo) and used identical System devices. The primary efficacy variable was the time-weighted summed pain intensity difference over the 48-hour study period (SPID48). Key secondary efficacy variables included pain intensity and pain relief scores, patient global assessments, patient and nurse ease of care scores and rescue medication consumption. Typical safety assessments were performed. RESULTS: A total of 426 patients were randomized (321 to SSMS and 105 to Placebo) and 315 and 105, respectively, received study drug and were included in the intent-to-treat population. Of those, 258 patients (62%) completed the 48h study period (68% in the SSMS group and 41% in the Placebo group). The most common reason for early termination was lack of efficacy (14% - SSMS and 48% - Placebo). The primary efficacy variable, time-weighted SPID48 was statistically significant in favor of the SSMS over Placebo (LS mean vs ; p ). Key secondary variables were similarly positive in favor of the SSMS group over placebo. The most frequently reported AEs were nausea (48.0%), pyrexia (17.2%), and vomiting (11.0%). A significantly higher proportion of patients in the SSMS group had nausea (52.7% vs. 33.7%; p < 0.001), dizziness (6.0% vs. 1.0%; p = 0.034), and pruritus (6.0% vs. 0%; p = 0.006) compared with the placebo group. Most AEs were mild or moderate in severity. CONCLUSION: SSMS provides an attractive alternative to traditional IV PCA analgesia, is easy for healthcare professionals to set-up and for patients to use. Introduction The sufentanil sublingual microtablet system (SSMS; ZALVISO TM, AcelRx Pharmaceuticals, Redwood City, USA) is a novel preprogrammed noninvasive product candidate currently under review at the Food and Drug Administration that dispenses small (3 mm diameter) sufentanil 15 mcg microtablets sublingually with a 20-minute lockout period (Figure 1). Sufentanil possesses a high therapeutic index (26,716 compared to 71 for morphine) 1 and rapid equilibration between plasma and CNS (t ½keo = 6min compared to 2.8 hrs for morphine) 2,3 (Table 1), however, rapid redistribution from plasma following IV administration and short duration of action make it less than ideal for intravenous patient-controlled analgesia (IV PCA). IV PCA, particularly with morphine, is commonly used for the management of moderate-to-severe post-operative pain. However, its use is associated with limitations, including the use of low therapeutic index opioids, the risk of pump programming errors and reduced patient mobility due to IV tethering. Figure 1. ZALVISO (sufentanil sublingual microtablet system) Methods Table 1. Comparisons of Therapeutic Index and t ½ke0 Therapeutic index t ½ke0 (min) Morphine Hydromorphone Meperidine Fentanyl Sufentanil 26, Note that M6G (morphine-6-glucuronide) has a t ½ke0 of 384 minutes (6.4 h) 6 The study objectives were to compare the safety and efficacy of SSMS to placebo delivered via the SSMS device for the management of moderate-to-severe post-operative pain after major orthopedic surgery. After IEC/IRB approval and patient informed consent, 440 post-operative inpatients (18 years and older) were to be randomized (3:1 to SSMS 15 mcg or placebo using identical devices to deliver study drug sublingually) to ensure at least 400 total patients (300 in the SSMS group and 100 in the placebo group) would receive study drug and provide primary efficacy data (90% power) for analysis. The primary efficacy variable was time-weighted summed pain intensity difference over the 48h study period (SPID48) using an 11-point numerical rating scale. Key secondary efficacy variables included pain intensity and pain relief scores (5-point categorical scale) over the study period, % of patients reporting success ( good or excellent rating) on the patient or healthcare professional global assessments of method of pain control over 48h using a 4- point categorical scale (PGA48/HPGA48), patient and nurse ease of care (EOC) scores (using a validated EOC questionnaire), and rescue medication consumption. Safety assessments included spontaneous adverse event (AE) reports, vital signs, medical history, physical examinations, oxygen saturation measurements, and concomitant medication usage. Results The study was conducted at 34 US sites from August 2012 to April A total of 533 patients were screened and 426 were randomized, with 321 and 105 allocated to the SSMS and placebo groups, respectively, and 315 and 104 who received study drug. Average patient age (years) was 66.6 and 65.0 in the SSMS and placebo groups, respectively. Most patients in the SSMS and placebo groups were female (70% and 84%, respectively). 215 patients (68.3%) in the SSMS group completed the 48h study period compared to 43 (41.3%) in the placebo group. Early drop-outs in the SSMS and placebo groups, respectively, were due to adverse events (7.0% vs. 6.7%), lack of efficacy (14.3% vs. 48.1%), and other (8.9% vs. 3.8%) (Table 2). Results (cont.) SSMS was superior to placebo for the SPID48 primary endpoint (least squares [LS] means 76.2 vs , p ). Key secondary variables were similarly positive in favor of the SSMS group over placebo (Table 3). Figure 2 shows the Kaplan-Meier cumulative event rate for time to termination from the study due to inadequate analgesia. LS mean SPID values by evaluation timepoint are shown in Figure 3. Secondary endpoint data showed that SPID24 and SPID72 were better in the SSMS group than placebo (p for both; not shown). SSMS was superior to placebo for timeweighted summed pain relief over 48h (TOTPAR48) (Table 3) and PGA/HPGA (Table 3). The mean inter-dose interval was 83.7 and 58.9 minutes for SSMS and placebo, respectively (p ). Rescue or supplemental morphine consumption was significantly higher in the placebo group at all timepoints from 6 through 48h (p 0.002). Both groups expressed high satisfaction with System use on the EOC questionnaire, not surprising since identical Systems were used to deliver sufentanil or placebo microtablets, however the mean pain control subscale score and patient satisfaction with level of pain control were significantly higher in the SSMS group (p for both; not shown). Table 2. Patient Disposition and Reasons for Early Discontinuation Randomized SSMS Placebo Total n=321 (%) n=105 (%) n=426 (%) Did not receive treatment Received non-randomized treatment Safety and efficacy ITT population 315 (100%) 104 (100%) 419 (100%) Study Completer (48-h period) 215 (68.3%) 43 (41.3%) 258 (61.6%) Discontinued study prior to 48h 100 (31.7%) 61 (58.7%) 161 (38.4%) Reason for discontinuation before 48h Adverse event 22 (7.0%) 7 (6.7%) 29 (6.9%) Lack of efficacy 45 (14.3%) 50 (48.1%) 95 (22.7%) Subject request 4 (1.3%) 0 (0%) 4 (1.0%) Other a 28 (8.9%) 4 (3.8%) 32 (7.6%) a Other reasons included: patient discharged from hospital prior to 48 hours (19 SSMS group, 3 Placebo group); patient no longer needed narcotic or opioid pain medication (3 SSMS group); System technical error or malfunction (4 SSMS group); insufficient drug at study site (1 Placebo group); patient switched to oral medications (2 SSMS group). Table 3. Key Secondary Variables (ITT Population) Key Secondary Endpoints Time-weighted SPID24 and SPID72 (LS mean) Time-weighted TOTPAR24, TOTPAR48, and TOTPAR72 (LS mean) Cumulative event rate for time to discontinuation due to inadequate analgesia (hrs) Proportion of patients who discontinued due to inadequate analgesia Note: HPGA## = healthcare professional global assessment of method of pain control over 24, 48, or 72 hours; ITT = intent-to-treat; LS = least squares; PGA## = patient global assessment of method of pain control over 24, 48, or 72 hours; SPID## = summed pain intensity differences over 24, 48 or 72 hours; SSMS = sufentanil sublingual microtablet system, success = a good or excellent response on the PGA/HPGA using a 4-point categorical scale; TOTPAR## = summed pain relief scores over 24, 48 or 72 hours Figure 2. Kaplan-Meier Cumulative Event Rates for Time to Termination due to inadequate analgesia SSMS n=315 (%) Placebo n=104 (%) P-value N/A % 48.1% Time to first rescue opioid use (hrs) Proportion of patients requiring rescue opioid 50.8% 73.1% Mean cumulative rescue/supplemental opioid doses consumed over 48h Proportion of patients reporting success on PGA24, PGA48, and PGA72 Proportion of HCPs reporting success on HPGA24, HPGA48 and HPGA % 70.2% 71.4% 70.2% 69.8% 70.8% 32.7% 28.8% 31.7% 33.7% 27.9% 28.8% Figure 3. LS Mean of SPID by Evaluation Timepoint Results (cont.) 351 Galveston Drive Redwood City, CA Safety Results: Table 4 shows the treatment-emergent adverse event summary. Related adverse events with an occurrence greater than 3% in either the sufentanil group or the placebo group are shown in Table 5. The most frequently reported related AEs were nausea and vomiting. All reported cases of itching in the trial were mild in nature. One placebo patient and 7 SSMS patients experienced severe AEs (oxygen saturation decreased [2], nausea [1], and chills [1] were deemed related). All other AEs were mild to moderate. Six SAEs were reported in the SSMS group - events of oxygen saturation decreased, sinus tachycardia, confusional state, and pneumonia aspiration were deemed possibly related. Table 4. Adverse Event Summary Patients SSMS Placebo Received treatment 315 (100%) 104 (100%) with at least one AE 264 (83.8%) 64 (61.5%) with at least one severe AE 7 (2.2%) 1 (1.0%) with at least one related AE 171 (54.3%) 35 (33.7%) with an SAE 6 (1.9%) 1 (1.0%) Table 5. Frequent Possibly or Probably Related Adverse Events (at least 3% in either group) SSMS (n = 315) Placebo (n = 104) p-value* Nausea 110 (34.9%) 23 (22.1%) Vomiting 34 (10.8%) 6 (5.8%) ns Oxygen saturation decreased 22 (7.0%) 3 (2.9%) ns Dizziness 16 (5.1%) 1 (1.0%) ns Constipation 15 (4.8%) 1 (1.0%) ns Pruritus 15 (4.8%) 0 (0.0%) Headache 13 (4.1%) 6 (5.8%) ns Insomnia 13 (4.1%) 3 (2.9%) ns Hypotension 12 (3.8%) 2 (1.9%) ns *Based on a two-sided Fisher s exact test. Note: ns = not significant; p > Continuous pulse oximetry was used during the study. An inability to maintain saturation above 95% despite oxygen supplementation resulted in an early discontinuation. Conclusions Patients receiving active SSMS demonstrated a significantly better SPID48 compared to placebo SSMS-treated patients during the study period (p ). The SSMS was effective and well-tolerated in the management of moderate-to-severe post-operative pain after major orthopedic surgery. Related adverse events were similar to placebo with the exception of nausea and itching SSMS provides an alternative to traditional IV PCA which is easy for healthcare professionals to set up and patients to use. References 1. Mather LE. Opioids: a pharmacologist s delight! Clin Exp Pharmacol Physiol 1995; 22: Lotsch J. Pharmacokinetic-pharmacodynamic modeling of opioids. J Pain Symptom Manage 2005; 29(5 Suppl):S90-S Scott JC et al. Electroencephalographic quantitation of opioid effect: comparative pharmacodynamics of fentanyl and sufentanil. Anesthesiol 1991; 74: Kumar P et al. Hydromorphone efficacy and treatment protocol impact on tolerance and μ-opioid receptor regulation. Eur. J. Pharmacol; 597: 39, 2008 (re: ED 50 ) and Purdue Pharma MSDS, 2009 (re: LD 50 ). 5. Shafer SL, Flood P. The Pharmacology of Opioids. In Geriatric Anesthesiology 2007; Ch. 15, Table 15-1; Springer Verlag, New York. 6. Lotsch et al. The transfer half-life of morphine-6-glucuronide from plasma to effect site assessed by pupil size measurement in healthy volunteers. Anesthesiol 2001; 95: Poster presentation at the Orthopedics Today Hawaii 2014, January 19-23, 2014 at the Grand Wailea, Maui, HI. Acknowledgements: AcelRx Pharmaceuticals (Redwood City, CA), the study sponsor, wishes to thank the study subjects, PharmaNet/i3, a subsidiary of Inventiv Health Clinical, the research coordinators and the investigators for their contribution.
Sufentanil Sublingual Tablet System 15mcg vs IV PCA Morphine: A Comparative Analysis of Patient Satisfaction and Drug Utilization by Surgery Type
Sufentanil Sublingual Tablet System 15mcg vs IV PCA Morphine: A Comparative Analysis of Patient Satisfaction and Drug Utilization by Surgery Type 2016 European Society of Regional Anesthesia Congress Maastricht,
More informationEfficacy and Safety of Sublingual Sufentanil 30 mcg for the Management of Acute Pain Following Ambulatory Surgery. Pamela P.
Efficacy and Safety of Sublingual Sufentanil 30 mcg for the Management of Acute Pain Following Ambulatory Surgery Pamela P. Palmer, MD, PhD Disclosures for Dr. Pamela Palmer AcelRx employee Currently own
More informationSufentanil Sublingual Tablet System for the Management of Postoperative Pain after Knee or Hip Arthroplasty
Sufentanil Sublingual Tablet System for the Management of Postoperative Pain after Knee or Hip Arthroplasty A Randomized, Placebo-controlled Study Maurice Jove, M.D., David W. Griffin, M.D., Harold S.
More informationForward Looking Statements
September 2015 Forward Looking Statements This presentation contains forward-looking statements including, but not limited to, statements related to future financial results including AcelRx s plans to
More informationPhase 3 Efficacy and Safety Results of Sufentanil Sublingual Tablet
Phase 3 Efficacy and Safety Results of Sufentanil Sublingual Tablet 2016 MHSRS Plenary Session Pamela Palmer, MD PhD Chief Medical Officer, AcelRx Pharmaceuticals, Inc. Treatment Considerations for Battlefield
More informationSingle- and Repeat-Dose Pharmacokinetics of Sublingual Sufentanil NanoTab in Healthy Volunteers
Single- and Repeat-Dose Pharmacokinetics of Sublingual Sufentanil NanoTab in Healthy Volunteers Pamela P. Palmer, MD, PhD AcelRx Pharmaceuticals, Inc. October 20, 2009 1 Sufentanil: A Superior Opioid Approved
More informationPhase 3 Efficacy and Safety Results of the Sufentanil Sublingual Tablet 30 mcg (DSUVIA )
Phase 3 Efficacy and Safety Results of the Sufentanil Sublingual Tablet 30 mcg (DSUVIA ) 2017 SOMSA Plenary Session Mark Evashenk VP Clinical Affairs, AcelRx Pharmaceuticals, Inc. Challenges with Management
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME / GENERIC DRUG NAME: Advil / Ibuprofen
More informationImmediate-release Hydrocodone/Acetaminophen M Abbreviated Clinical Study Report R&D/08/1020
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Hydrocodone Bitartrate- Acetaminophen (NORCO ) Name of
More informationA randomised, double-blind, parallel group, multicentre study to compare the tolerability, safety, and efficacy of oxycodone with morphine in
A randomised, double-blind, parallel group, multicentre study to compare the tolerability, safety, and efficacy of oxycodone with morphine in patients using i.v. patient-controlled analgesia (PCA) for
More informationCorporate overview. December Exploring innovative solutions for acute pain
Corporate overview December 2017 Exploring innovative solutions for acute pain Forward-looking statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationUse of Pregabalin for Postoperative Pain: Outcomes in 2 Trials
Use of Pregabalin for Postoperative Pain: Outcomes in 2 Trials Jacques E. Chelly, 1 Neil Singla, 2 David R. Lionberger, 3 Henrik Kehlet, 4 Luis Sanin, 5 Jonathan Sporn, 5 Ruoyong Yang, 5 Raymond C. Cheung,
More informationCorporate overview. September Exploring innovative solutions for acute pain
Corporate overview September 2017 Exploring innovative solutions for acute pain Forward-looking statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationSufentanil Sublingual Tablet 30 mcg for the Management of Pain Following Abdominal Surgery: A Randomized, Placebo-Controlled, Phase-3 Study
ORIGINAL ARTICLE Sufentanil Sublingual Tablet 30 mcg for the Management of Pain Following Abdominal Surgery: A Randomized, Placebo-Controlled, Phase-3 Study Harold S. Minkowitz, MD*; David Leiman, MD ;
More informationA Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Analgesic Efficacy of MNK-795 Controlled-Release
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Analgesic Efficacy of MNK-795 Controlled-Release Oxycodone/Acetaminophen Tablets (CR OC/APAP) in an Acute Pain Model Neil
More informationDsuvia (sufentanil) NEW PRODUCT SLIDESHOW
Dsuvia (sufentanil) NEW PRODUCT SLIDESHOW Introduction Brand name: Dsuvia Generic name: Sufentanil Pharmacological class: Opioid agonist Strength and Formulation: 30mcg; sublingual tabs (housed in a disposable,
More informationWhat s New in Post-Cesarean Analgesia?
Anesthesia & Obstetrics What s New in Post-Cesarean Analgesia? October 23rd, 2013 2013 UCSF What Does The Evidence Tell Us? Mark Rollins, MD, PhD UC SF Post-Delivery Pain (Mean pain scores for first 24
More information(For National Authority Use Only) Name of Study Drug: to Part of Dossier:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Vicodin CR Name of Active Ingredient: Page: Hydrocodone/Acetaminophen
More informationThe intensity of preoperative pain is directly correlated with the amount of morphine needed for postoperative analgesia
The intensity of preoperative pain is directly correlated with the amount of morphine needed for postoperative analgesia This study has been published: The intensity of preoperative pain is directly correlated
More informationHydrocodone/Acetaminophen Extended-Release Tablets M Clinical Study Report R&D/09/1109
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-712 Volume: Hydrocodone/Acetaminophen Extended-Release Name
More informationSatisfactory Analgesia Minimal Emesis in Day Surgeries. (SAME-Day study) A Randomized Control Trial Comparing Morphine and Hydromorphone
Satisfactory Analgesia Minimal Emesis in Day Surgeries (SAME-Day study) A Randomized Control Trial Comparing Morphine and Hydromorphone HARSHA SHANTHANNA ASSISTANT PROFESSOR ANESTHESIOLOGY MCMASTER UNIVERSITY
More informationEffective pain management begins with OFIRMEV (acetaminophen) injection FIRST Proven efficacy with rapid reduction in pain 1
Effective pain management begins with OFIRMEV (acetaminophen) injection FIRST Proven efficacy with rapid reduction in pain 1 Fast onset of pain relief with 7% reduction in visual analog scale (VAS) scores
More informationI.V. CR845 Adaptive Phase 2/3 Post Operative Pain Study Results
I.V. CR845 Adaptive Phase 2/3 Post Operative Pain Study Results A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study Evaluating the Analgesic Efficacy and Safety of I.V. CR845
More informationAcelRx Pharmaceuticals. Corporate Presentation First Quarter 2016
AcelRx Pharmaceuticals Corporate Presentation First Quarter 2016 Forward-Looking Statements This presentation contains forward-looking statements including, but not limited to, statements related to the
More informationAcelRx Pharmaceuticals. Corporate Presentation June 2016
AcelRx Pharmaceuticals Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements related to the process
More informationMorphiDex (MS:DM) Double-Blind, Multiple-Dose Studies In Chronic Pain Patients
Vol. 19 No. 1(Suppl.) January 2000 Journal of Pain and Symptom Management S37 Proceedings Supplement NMDA-Receptor Antagonists: Evolving Role in Analgesia MorphiDex (MS:DM) Double-Blind, Multiple-Dose
More informationSupport for Acetaminophen 1000 mg Over-the-Counter Dose:
Support for Acetaminophen 1000 mg Over-the-Counter Dose: The Dental Impaction Pain Model and Efficacy and Safety Results from McNeil Randomized, Double-Blind, Single-Dose Study of Acetaminophen 1000 mg,
More informationIntravenous Dezocine for Postoperative Pain: A Double-Blind, Placebo-Controlled Comparison With Morphine
Intravenous for Postoperative Pain: A Double-Blind, Placebo-Controlled Comparison With Morphine Uma A. Pandit, MD, S aria P. Kothary, MD, and Sujit K. Pandit, MD, PhD, a new mixed agonist-antagonist opioid
More informationAVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018
AVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationBalanced Analgesia With NSAIDS and Coxibs. Raymond S. Sinatra MD, Ph.D
Balanced Analgesia With NSAIDS and Coxibs Raymond S. Sinatra MD, Ph.D Prostaglandins and Pain The primary noxious mediator released from damaged tissue is prostaglandin (PG) PG is responsible for nociceptor
More informationCorporate Overview. March 2018
Corporate Overview March 2018 Forward looking statements This presentation contains forward looking statements, including, but not limited to, statements related to financial results and trends; the process
More informationDigital RIC. Rhode Island College. Linda M. Green Rhode Island College
Rhode Island College Digital Commons @ RIC Master's Theses, Dissertations, Graduate Research and Major Papers Overview Master's Theses, Dissertations, Graduate Research and Major Papers 1-1-2013 The Relationship
More informationOFIRMEV a non-opioid, non-nsaid, intravenous analgesic for the management of pain
FOR PHARMACY PROFESSIONALS In pharmacokinetic studies Rapid time to reach Cmax with IV acetaminophen OFIRMEV from the start OFIRMEV g demonstrated early and high Cmax at minutes Consider administering
More informationDORIS DUKE MEDICAL STUDENTS JOURNAL Volume V,
Continuous Femoral Perineural Infusion (CFPI) Using Ropivacaine after Total Knee Arthroplasty and its Effect on Postoperative Pain and Early Functional Outcomes Eric Lloyd Scientific abstract Total Knee
More informationParecoxib, Celecoxib and Paracetamol for Post Caesarean Analgesia: A Randomised Controlled Trial
Parecoxib, Celecoxib and Paracetamol for Post Caesarean Analgesia: A Randomised Controlled Trial McDonnell NJ, Paech MJ, Baber C, Nathan E Clinical Associate Professor Nolan McDonnell School of Medicine
More informationCurrent evidence in acute pain management. Jeremy Cashman
Current evidence in acute pain management Jeremy Cashman Optimal analgesia Best possible pain relief Lowest incidence of side effects Optimal analgesia Best possible pain relief Lowest incidence of side
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Transmucosal Fentanyl Effective Date... 4/15/2018 Next Review Date... 4/15/2019 Coverage Policy Number... 1018 Table of Contents Coverage Policy... 1 General
More informationBird M : Acute Pain Management: A New Area of Liability for Anesthesiologist. ASA Newsletter 71(8), 2007.
Citation Bird M : Acute Pain Management: A New Area of Liability for Anesthesiologist. ASA Newsletter 71(8), 2007. Full Text A 71-year-old obese female smoker with hypertension and diabetes underwent a
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Trial Results with OROS Ò Hydromorphone
Vol. 33 No. 2S February 2007 Journal of Pain and Symptom Management S25 Advances in the Long-Term Management of Chronic Pain: Recent Evidence with OROS Ò Hydromorphone, a Novel, Once-Daily, Long-Acting
More informationIntravenous lidocaine infusions. Dr Ian McConachie FRCA FRCPC
Intravenous lidocaine infusions Dr Ian McConachie FRCA FRCPC Thank the organisers for inviting me. No conflicts or disclosures Lidocaine 1 st amide local anesthetic Synthesized in 1943 by Lofgren in Sweden.
More informationHTX-011, a Proprietary, Unique, Long-Acting Local Anesthetic, Reduces Acute Postoperative Pain Intensity and Opioid Consumption Following Bunionectomy
HTX-011, a Proprietary, Unique, Long-Acting Local Anesthetic, Reduces Acute Postoperative Pain Intensity and Opioid Consumption Following Bunionectomy Eugene Viscusi, 1 Oscar DeLeon-Casasola, 2 TJ Gan,
More informationRespiratory Effects of IV CR845 - A Peripherally Acting, Selective Kappa Opioid Receptor Agonist
Respiratory Effects of IV CR845 - A Peripherally Acting, Selective Kappa Opioid Receptor Agonist Eugene R. Viscusi, 1 Marc C. Torjman, 1 Joseph W. Stauffer, 2 Catherine L. Munera, 2 Beatrice S. Setnik,
More informationComparison of fentanyl versus fentanyl plus magnesium as post-operative epidural analgesia in orthopedic hip surgeries
Original Research Article Comparison of fentanyl versus fentanyl plus magnesium as post-operative epidural analgesia in orthopedic hip surgeries P V Praveen Kumar 1*, Sreemanth 2 1 Associate Professor,
More informationIs Local Infiltration Analgesia (LIA) a Safe and Effective Method for Post-Operative Pain Management After a Unilateral Total Knee Arthroplasty (TKA)?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2013 Is Local Infiltration Analgesia (LIA)
More informationIndividual Study Table Referring to Part of the Dossier. Page:
2. SYNOPSIS Title of Study: A phase III comparative study of the pharmacokinetic/pharmacodynamic and safety profiles of extended release, regular release and placebo during a 12 hour observation in post-extraction
More informationDaniel Canafax, PharmD VP, Clinical Research Theravance, Inc.
Demonstrates Improvement in Bowel Movement Frequency and Bristol Stool Scores in a Phase 2b Study of Patients with Opioid-Induced Constipation (OIC) Ross Vickery, PhD, 1 Yu-Ping Li, PhD, 1 Ullrich Schwertschlag,
More informationCENTRAL IOWA HEALTHCARE Marshalltown, Iowa
CENTRAL IOWA HEALTHCARE Marshalltown, Iowa CARE OF PATIENT POLICY & PROCEDURES Policy Number: 4.84 Subject: Policy: Purpose: Continuous Epidural Analgesia Acute or chronic pain relief provided to a patient
More informationOvercoming Opioid-Induced Oversedation: More Than Meets the Eye
Overcoming Opioid-Induced Oversedation: More Than Meets the Eye ANCC National Magnet Conference 2013 Jeannine M. Brant, PhD, APRN, AOCN Lisa Peterson, RN-BC, BSN Health Care, Education and Research www.billingsclinic.com
More informationINDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER. Volume: Page:
SYNOPSIS Protocol No: OROS-ANA-3001 Title of Study: Randomized, open-label, comparative parallel group study to assess efficacy and safety of flexible dosages of OROS hydromorphone once-daily compared
More informationNew Methods for Analgesia Delivery
New Methods for Analgesia Delivery Guy Ludbrook MBBS PhD FANZCA Royal Adelaide Hospital and University of Adelaide South Australia Anesthesiology is on the verge of a major evolution that will involve
More informationType of intervention Anaesthesia. Economic study type Cost-effectiveness analysis.
Comparison of the costs and recovery profiles of three anesthetic techniques for ambulatory anorectal surgery Li S T, Coloma M, White P F, Watcha M F, Chiu J W, Li H, Huber P J Record Status This is a
More informationAllergan Not Applicable AGN A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose, Parallel
Peripheral Neuropathy Design, Dose Ranging Study of the Safety and Efficacy of AGN 203818 in Patients with Painful Diabetic 203818-004. A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple
More informationInnovative Approaches and New Technology to Gain Access
Innovative Approaches and New Technology to Gain Access The following is intended only for presentation to the Reimbursement and Access 2017 audience, August 17, 2017. This information is not for promotional
More informationPHYSICIAN COMPETENCY FOR ADULT DEEP SEDATION (Ages 14 and older)
Name Score PHYSICIAN COMPETENCY FOR ADULT DEEP SEDATION (Ages 14 and older) 1. Pre-procedure evaluation for moderate sedation should involve all of the following EXCEPT: a) Airway Exam b) Anesthetic history
More informationStudy No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAvenue Therapeutics, Inc. September 2016
Avenue Therapeutics, Inc. September 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the
More informationGabapentin Does Not Improve Analgesia Outcomes For Total Joint Replacement. Manyat Nantha-Aree, MD
Gabapentin Does Not Improve Analgesia Outcomes For Total Joint Replacement Manyat Nantha-Aree, MD Objective n Preliminary results of MOBILE study in total hip and knee arthroplasty Background n Gabapentin=
More informationCAM2038 A new liquid-lipid crystal depot buprenorphine: A dose-ranging suite of weekly and monthly subcutaneous depot injections
CAM2038 A new liquid-lipid crystal depot buprenorphine: A dose-ranging suite of weekly and monthly subcutaneous depot injections Dr. Fredrik Tiberg Assoc. Prof. President & CEO, Head R&D, Camurus Lund,
More informationPeri operative pain control. Disclosure. Objectives 9/1/2011. No current conflicts of interest
Peri operative pain control Chris Herndon, PharmD, FASHP Southern Illinois University Edwardsville Disclosure No current conflicts of interest Objectives Discuss studies evaluating the transformation of
More informationSubspecialty Rotation: Anesthesia
Subspecialty Rotation: Anesthesia Faculty: John Heaton, M.D. GOAL: Maintenance of Airway Patency and Oxygenation. Recognize and manage upper airway obstruction and desaturation. Recognize and manage upper
More informationA service of the U.S. National Institutes of Health Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
A service of the U.S. National Institutes of Health w Available: Final Rule for FDAAA 81 and NIH Policy on Clinical Trial Reporting Trial record 1 of 1 for: FENHYDPAI414 Previous Study Return to List Next
More informationStudy Center(s): The study was conducted at 39 study sites in Japan.
SYNOPSIS Issue Date: 20 NOVEMBER 2012 Name of Sponsor/Company Janssen Pharmaceutical K. K. Name of Finished Product CONCERTA Name of Active Ingredient(s) Methylphenidate HCl Protocol No.: JNS001-JPN-A01
More informationSubstitution Therapy for Opioid Use Disorder The Role of Suboxone
Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM
More informationPALLIATIVE TREATMENT BY DR. KHRONGKAMOL SIHABAN MEDICAL ONCOLOGIST
PALLIATIVE TREATMENT BY DR. KHRONGKAMOL SIHABAN MEDICAL ONCOLOGIST TREATMENT IN ONCOLOGY Main treatment : surgery Neoadjuvant treatment : RT, CMT Adjuvant treatment : Tx micrometastatic disease -CMT,Targeted
More informationOral Oxycodone for Acute Postoperative Pain: A Review of Clinical Trials. Pain Physician Opioid Special Issue 2017; 20:SE33-SE52
Pain Physician 2017; 20:SE33-SE52 ISSN 2150-1149 Narrative Review Oral Oxycodone for Acute Postoperative Pain: A Review of Clinical Trials Chi Wai Cheung, MD 1, Stanley Sau Ching Wong, MBBS 1, Qiu Qiu,
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationRemifentanil PCA In Labor
Remifentanil PCA In { Jennifer Lucero, MD Clinical Instructor UCSF Department of Anesthesia Remifentanil PCA in Discuss the Pharmokinectics of Remifentanil Review literature on the use of Remifentanil
More informationMr David A McDonald Service Improvement Manager Whole System patient Flow Improvement Programme Scottish Government
Mr David A McDonald Service Improvement Manager Whole System patient Flow Improvement Programme Scottish Government Introduction Brief update Two main topics Use of Gabapentin Local Infiltration Analgesia
More informationIndividual Study Table Referring to Part of the Dossier. Page:
2. SYNOPSIS Title of Study: A comparative study of the pharmacokinetic/pharmacodynamic and safety profiles of extended release, regular release and placebo during a 12 hour observation in post-extraction
More information(30689) PROT Pain PCA Adult Patient Controlled Analgesia
Diagnosis Allergies Nursing Assess and Document PCA: 1. Assess and document pain rating, sedation level and respiratory rate every 2 hours; assess and document pain rating, sedation level and respiratory
More information5 th ERAS UK Conference. Advances in Pain Management. Jayne Balson Advanced Nurse Specialist Pain Management Western General Hospital Edinburgh
5 th ERAS UK Conference Advances in Pain Management Jayne Balson Advanced Nurse Specialist Pain Management Western General Hospital Edinburgh Pre-op information Optimised organ function No nutritional
More informationIntraspinal (Neuraxial) Analgesia Community Nurses Competency Test
Intraspinal (Neuraxial) Analgesia Community Nurses Competency Test 1 Intraspinal (Neuraxial) Analgesia for Community Nurses Competency Test 1) Name the two major classifications of pain. i. ii. 2) Neuropathic
More informationENHANCED RECOVERY PROTOCOLS FOR KNEE REPLACEMENT
ENHANCED RECOVERY PROTOCOLS FOR KNEE REPLACEMENT Jeff Gadsden, MD, FRCPC, FANZCA Associate Professor Duke University Department of Anesthesiology Regional Anesthesia and Acute Pain Medicine DISCLOSURES
More informationPOST OPERATIVE PAIN MANAGEMENT: PAIN AND COMPLICATIONS
POST OPERATIVE PAIN MANAGEMENT: PAIN AND COMPLICATIONS November 9, 2018 Aimee LaMere, CNP Molly McNaughton, CNP Leslie Weide, MSW, LICSW, ACM Disclosures: Conflict of interest statement: We certify that,
More informationAVENUE THERAPEUTICS, INC. NASDAQ: ATXI NOV 2018
AVENUE THERAPEUTICS, INC. NASDAQ: ATXI NOV 2018 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning
More informationLabor Epidural: Local Anesthetics and Beyond
Goals: Labor Epidural: Local Anesthetics and Beyond Pedram Aleshi MD The Changing Practice of Anesthesia September 2012 Review Concept of MLAC Local anesthetic efficacy Local anesthetic sparing effects:
More informationPerioperative Pain Management
Perioperative Pain Management Overview and Update As defined by the Anesthesiologist's Task Force on Acute Pain Management are from the practice guidelines from the American Society of Anesthesiologists
More informationOral Methylnaltrexone for the. Constipation in Patients with Chronic Non-cancer Pain
Oral Methylnaltrexone for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain Richard L. Rauck, 1 John F. Peppin, 2 Robert J.Israel, 3 Jennifer Carpenito, 3 Jeffrey Cohn,
More informationScottish Medicines Consortium
Scottish Medicines Consortium fentanyl 50 micrograms / dose, 100 micrograms/dose, 200 micrograms / dose nasal spray (Instanyl ) No. (579/09) Nycomed UK Ltd 09 October 2009 The Scottish Medicines Consortium
More informationClinical Trial Results Summary Study EN3409-BUP-305
Title of Study: A 52-Week, Open-Label, Long-Term Treatment Evaluation of the Safety and Efficacy of BEMA Buprenorphine in Subjects with Moderate to Severe Chronic Pain Coordinating Investigator: Martin
More informationVAN WERT COUNTY HOSPITAL. Policy/Procedure: Departmental No.: N 11-36A. Issue Date: 7-97 By: Nursing No. of Pages: 6
VAN WERT COUNTY HOSPITAL Policy/Procedure: Departmental No.: N 11-36A Issue Date: 7-97 By: Nursing No. of Pages: 6 Reviewed: 9-14, 8-11, 8-10 Revised: 9-14 Distribution List: All Nursing Departments Concurrence:
More informationAnesthesia for Total Hip and Knee Arthroplasty
Anesthesia for Total Hip and Knee Arthroplasty Typical approach Describe anesthesia technique Rather Describe issues with THA and TKA How anesthesia can modify Issues Total Hip Total Knee Blood Loss ++
More informationI ve Got You Under My Skin: A Comparison of IV and s/c PCA. Nick Williamson Clinical Nurse Specialist
I ve Got You Under My Skin: A Comparison of IV and s/c PCA Nick Williamson Clinical Nurse Specialist How did PCA get under my skin? Started in 2009 when I started working at KCH Subcut PCA!!! PCA refers
More informationSynopsis (C1034T02) CNTO 95 Module 5.3 Clinical Study Report C1034T02
Module 5.3 Protocol: EudraCT No.: 2004-002130-18 Title of the study: A Phase 1/2, Multi-Center, Blinded, Randomized, Controlled Study of the Safety and Efficacy of the Human Monoclonal Antibody to Human
More informationHTX-011 Postoperative Pain Program Topline Results from Phase 2b Studies. June 21, 2018
HTX-011 Postoperative Pain Program Topline Results from Phase 2b Studies June 21, 2018 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities
More informationNYSPFP Kickoff. Reducing Adverse Drug Events from Opioids. April 6, 2017
NYSPFP Kickoff Reducing Adverse Drug Events from Opioids April 6, 2017 I have no financial relationships with drug companies, durable medical equipment companies or other for profit entities related to
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive
More informationResponding to The Joint Commission Alert on Safe Use of Opioids in Hospitals
Responding to The Joint Commission Alert on Safe Use of Opioids in Hospitals Suzanne A Nesbit, PharmD, CPE Clinical Pharmacy Specialist, Pain Management The Johns Hopkins Hospital Objectives and Disclosures
More informationCONCERNED ABOUT TAKING OPIOIDS AFTER SURGERY?
CONCERNED ABOUT TAKING OPIOIDS AFTER SURGERY? ASK YOUR DOCTOR ABOUT EXPAREL FOR LONG-LASTING, NON-OPIOID PAIN RELIEF. VISIT EXPAREL.com/patient FOR MORE INFORMATION. YOU HAVE A SAY IN HOW YOUR PAIN IS
More informationPost Caesarean Analgesia An Update. Kim Ekelund MD, PhD, associate professor Rigshospitalet Copenhagen, Denmark
Post Caesarean Analgesia An Update Kim Ekelund MD, PhD, associate professor Rigshospitalet Copenhagen, Denmark Post caesarean analgesia No Conflicts of Interests Neuraxial opioids Multimodal therapy Plan
More informationWORRIED ABOUT PAIN AFTER ORAL SURGERY?
WORRIED ABOUT PAIN AFTER ORAL SURGERY? OPIOIDS ARE NOT THE ONLY WAY TO MANAGE PAIN Ask your doctor about opioid-free EXPAREL EXPAREL is indicated for single-dose infiltration in adults to produce postsurgical
More informationMalaysian Orthopaedic Journal 2008 Vol 2 No 2
Randomized Clinical Trial of Periarticular Drug Injection used in combination Patient-Controlled Analgesia versus Patient-Controlled Analgesia Alone in Total Knee Arthroplasty MN Sabran, MBBS, AJM Talha*,
More information2:39 2: Dizziness and nausea Cerebral. 2:57 1: Vomiting Gastro-intestinal
Supplemental: Table B: Detailed description of adverse events by time, treatment group and procedure T-spinal to incident T-spinal to PACU discharge Group THA/TKA Adverse event description Adverse event
More informationPATIENT CONTROLLED ANALGESIA LEARNING PACKAGE
1 PATIENT CONTROLLED ANALGESIA LEARNING PACKAGE 2 Table of Contents page# Learning Objectives 3 Concepts of Pain Relief 4 Introduction to PCA 4 Definition of terms used with IV PCA 6 Opioids used with
More informationAvenue Therapeutics, Inc. May 2017
Avenue Therapeutics, Inc. May 2017 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationPCA PRESCRIPTION is valid for a maximum of 4 days unless ceased earlier. Date: BINDING MARGIN - NO WRITING BINDING MARGIN - NO WRITING
Attach ADR Sticker THESE INSTRUCTIONS EXPLAIN WHEN TO MAKE A CLINICAL REVIEW OR RAPID RESPONSE CALL, YOUR LOCAL ESCALATION PROTOCOL WILL EXPLAIN HOW TO MAKE A CALL PCA ALLERGIES & ADVERSE DRUG REACTIONS
More information